As a national key high-tech enterprise and innovative pilot enterprise, taigui pharmaceutical has always adhered to the strategy of “revitalizing the enterprise through innovation” and independently established Shanghai R & D center, academician workstation and post doctoral research mobile station on the platform of Shanghai and Hangzhou.

The center has more than 100 R & D personnel, including 1 academician, 1 overseas engineer, 500 in Shanghai, 6 elite talents, 1 winner of West Lake Friendship Award and more than 30 masters. The center has extensive and in-depth cooperation with Chinese Academy of Sciences, East China Normal University, Zhejiang University, Fudan University and other domestic well-known universities and scientific research institutions, effectively realize the interaction and integration of information, talents, technology and other resources, and firmly build the strong strength of the company to rush to the forefront of science and technology.

The company has 20 years experience in custom research and development and production, products cover the process of starting materials, intermediates and apis. Industry has become taigui pharmaceutical research and development and customization of the core business, to provide global customers from the whole process of research and development to the commercial production services, at the same time the company assembled a PhD, master graduate student team, responsible for project management, research and development, customization and operation management, to ensure that the development of custom service high level, high quality and high efficiency.

The company has gradually mastered the technologies of biological fermentation, enzyme transformation and chemical synthesis, and has achieved a leading position in the industry. Moreover, with exquisite production technology advantages and rich industry experience, taigui pharmaceutical has effectively improved production efficiency and product quality, established long-term and stable cooperative relations with many large downstream customers of steroidal drugs at home and abroad, and gradually realized the growth of sales and even performance.

The company will also actively carry out R & D innovation and development planning. On the basis of the original production technology, the company will extend to the intermediates and API products of high-end steroid series by increasing R & D investment and external cooperation, layout new product lines, stimulate vitality, forge ahead and promote the upgrading and development of the enterprise.

Post time: Jun-03-2019